Varenicline and bupropion sustained-release combination therapy for smoking cessation
Varenicline and bupropion sustained-release combination therapy for smoking cessation
复制标题
DOI：
10.1093/ntr/ntn031
复制
发表时间：
2009-03-01
影响因子：
4.7
通讯作者：
Hurt, Richard D.
中科院分区：
文献类型：
--
作者：
Ebbert, Jon O.;Croghan, Ivana T.;Hurt, Richard D.
伐尼克兰和安非他酮缓释剂（SR）都是安全有效的治疗烟草依赖，并有不同的作用机制。这些药物的联合药物治疗可能会增加长期戒烟率以上是观察到与单一agenttherapy.We登记的香烟吸烟者在一个开放标签，单臂，II期临床试验，以获得初步数据的潜在有效性和安全性的联合治疗与伐尼克兰和安非他酮SR烟草依赖的治疗。符合条件的受试者接受伐尼克兰滴定至1.0 mg，口服，每日两次，安非他酮SR滴定至150 mg，口服，每日两次，共沿着12周的行为治疗。自我报告的戒烟被生化证实与过期的一氧化碳。共有38名吸烟者，平均年龄为49.1岁（SD = 12.4）平均每天吸烟19.9支（SD = 7.8）30年7天时点戒烟率3个月为71%（95%CI = 54%~ 85%），6个月为58%（95%CI = 41%~ 74%）。戒烟受试者在给药期间的平均体重变化为1.6 kg（SD = 2.4）。对于这两种药物，74%的受试者服用了至少90%的处方剂量。最常见的副作用是睡眠障碍（26%）和恶心（24%）。抑郁症状没有增加，没有受试者报告自杀ideation.Combination治疗与伐尼克兰和安非他酮SR可能是有效的增加吸烟戒烟率以上观察与单药治疗。
Varenicline and bupropion sustained release (SR) are both safe and effective for the treatment of tobacco dependence and have different mechanisms of action. Combination pharmacotherapy with these agents may increase long-term smoking abstinence rates above what is observed with single-agent therapy.We enrolled cigarettes smokers in an open-label, one-arm, Phase II clinical trial to obtain preliminary data on the potential effectiveness and safety of combination therapy with varenicline and bupropion SR for the treatment of tobacco dependence. Eligible subjects received varenicline titrated to 1.0 mg by mouth twice daily and bupropion SR titrated to 150 mg by mouth twice daily for a total of 12 weeks along with behavioral therapy. Self-reported smoking abstinence was biochemically confirmed with expired carbon monoxide. A total of 38 smokers with a mean age of 49.1 years (SD = 12.4) who smoked an average of 19.9 cigarettes/day (SD = 7.8) for 30 years (SD = 12.3) were enrolled.Seven-day point-prevalent smoking abstinence rates were 71% (95% CI = 54%-85%) at 3 months and 58% (95% CI = 41%-74%) at 6 months. Mean weight change during the medication phase among smoking-abstinent subjects was 1.6 kg (SD = 2.4). For both medications, 74% of subjects took at least 90% of the prescribed doses. The most common side effects were sleep disturbance (26%) and nausea (24%). No increase in depressive symptoms was observed, and no subjects reported suicidal ideation.Combination therapy with varenicline and bupropion SR may be effective for increasing smoking abstinence rates above that observed with monotherapy.